Back to Browse Journals » International Journal of Nanomedicine » Volume 6

Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy

Authors Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S

Published Date November 2011 Volume 2011:6 Pages 3011—3019

DOI http://dx.doi.org/10.2147/IJN.S26155

Published 24 November 2011

Anna Rita Bizzarri1, Simona Santini1, Emilia Coppari1, Monica Bucciantini2, Silvia Di Agostino3, Tohru Yamada4, Craig W Beattie4, Salvatore Cannistraro1
1
Biophysics and Nanoscience Centre, CNISM, Facoltà di Scienze, Università della Tuscia, Viterbo, 2Department of Biochemical Sciences, University of Florence, Florence, 3Molecular Oncogenesis Laboratory, Experimental Oncology Department, Regina Elena Cancer Institute, Rome, Italy; 4Department of Surgical Oncology, University of Illinois College of Medicine, Chicago, IL, USA

Abstract: p28 is a 28-amino acid peptide fragment of the cupredoxin azurin derived from Pseudomonas aeruginosa that preferentially penetrates cancerous cells and arrests their proliferation in vitro and in vivo. Its antitumor activity reportedly arises from post-translational stabilization of the tumor suppressor p53 normally downregulated by the binding of several ubiquitin ligases. This would require p28 to specifically bind to p53 to inhibit specific ligases from initiating proteosome-mediated degradation. In this study, atomic force spectroscopy, a nanotechnological approach, was used to investigate the interaction of p28 with full-length p53 and its isolated domains at the single molecule level. Analysis of the unbinding forces and the dissociation rate constant suggest that p28 forms a stable complex with the DNA-binding domain of p53, inhibiting the binding of ubiquitin ligases other than Mdm2 to reduce proteasomal degradation of p53.

Keywords: AFS, cancer physics, unbinding forces

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor

Domenici F, Bizzarri AR, Cannistraro S

International Journal of Nanomedicine 2011, 6:2033-2042

Published Date: 19 September 2011

Readers of this article also read:

Fibrin glue for Gundersen flap surgery

Chung HW, Mehta JS

Clinical Ophthalmology 2013, 7:479-484

Published Date: 6 March 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Intraperitoneal injection of magnetic Fe3O4-nanoparticle induces hepatic and renal tissue injury via oxidative stress in mice

Ma P, Luo Q, Chen J, Gan Y, Du J, Ding S, Xi Z, Yang X

International Journal of Nanomedicine 2012, 7:4809-4818

Published Date: 5 September 2012

Erratum

Todd Levine

Drug Design, Development and Therapy 2012, 6:163-164

Published Date: 21 June 2012

Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems

Jiang Z, Sun C, Yin Z, Zhou F, Ge L, Liu X, Kong F

International Journal of Nanomedicine 2012, 7:2019-2031

Published Date: 17 April 2012

Corrigendum

Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP

International Journal of Nanomedicine 2012, 7:1709-1710

Published Date: 30 March 2012

Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery

Stephen Smith, Douglas Lorenz, James Peace, et al.

Clinical Ophthalmology 2010, 4:983-991

Published Date: 30 August 2010

Bacterial endophthalmitis following 25-gauge transconjunctival sutureless vitrectomy

Drew N Sommerville, Dean P Hainsworth

Clinical Ophthalmology 2008, 2:935-936

Published Date: 18 September 2008

Comparing techniques for pterygium surgery

Atilla Alpay, Suat Hayri Ugurbas, Berktug Erdogan

Clinical Ophthalmology 2009, 3:69-74

Published Date: 17 September 2008